Core Viewpoint - The global gene sequencing industry is undergoing a competitive restructuring, prompting the company to optimize its global business layout and business model [1] Group 1: Business Transactions - The company announced the sale of 100% equity of its wholly-owned subsidiary CGI to Swiss Rockets for approximately $50 million, following the separation of related assets and liabilities [2] - The company has revised the previously signed CoolMPS sequencing technology licensing agreement to include exclusive licensing of StandardMPS sequencing technology, enhancing strategic collaboration with Swiss Rockets [2][3] - The transaction is seen as a key move for the company to replace "asset outflow" with "technology outflow" in a complex international environment [2] Group 2: Financial Implications - The company expects to receive at least $120 million in revenue from the new licensing agreement, which includes a $20 million upfront payment, a $20 million milestone payment, and tiered royalties based on net sales [4] - The transaction is anticipated to bring significant direct benefits and improve cash flow, as the company will receive approximately $50 million from the equity transfer and reduce losses from the underperforming CGI business unit [4] - The shift from high-volatility direct overseas operations to a structured, predictable revenue model is expected to enhance financial resilience [4] Group 3: Strategic Reorientation - The company has permanently and irrevocably licensed back 205 patents from CGI, ensuring the integrity of its technology system and business continuity for future global licensing [5] - The company will continue to lead the expansion of CoolMPS in the Asia-Pacific and Greater China regions while promoting StandardMPS globally outside the U.S. and Canada [5] - The move to transfer North American operations to a partner is a proactive adaptation to the current geopolitical and regulatory environment, allowing the company to maintain technology output and market penetration [6] Group 4: Industry Context - Swiss Rockets, established in 2018, focuses on innovative biopharmaceuticals and has rapidly expanded its asset scale, providing support for the collaboration [6] - The company is also enhancing its technology integration by acquiring 100% equity of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd., incorporating core capabilities in spatiotemporal omics and nanopore sequencing [6]

Group 1 - The company announced the signing of a share purchase agreement with Swiss Rockets AG to sell 100% equity of its wholly-owned subsidiary Complete Genomics, Inc. (CGI) for approximately $50 million, with the final transaction price subject to the delivery conditions [1] - The company’s wholly-owned subsidiary MGI US LLC, CGI, and Swiss Rockets have also signed an amendment to the licensing agreement, which will add the paid licensing of the company's StandardMPS sequencing technology and general sequencing technology to Swiss Rockets [1]